Poliovirus Therapy Wins 'Breakthrough' Status
News May 18, 2016
In a poignant, two-part segment May 15, CBS’s 60 Minutes returned to Duke to update viewers on the poliovirus therapy developed and tested by researchers at the Preston Robert Tisch Brain Tumor Center.
Anchor Scott Pelley again led the reporting of the program, which spanned more than two years. It provides major updates to the news magazine’s initial two-part segment, “Killing Cancer,” which aired March 29, 2015.
Sunday night’s segment revisited the work of Dr. Matthias Gromeier and featured interviews with neuro-oncologists Dr. Annick Desjardins and Dr. Henry Friedman, along with and brain tumor center director Dr. Darell Bigner, who are among many on Duke's poliovirus team.
The program also resumed where it left off in the journey of Nancy Justice and her family, who came to the Preston Robert Tisch Brain Tumor Center in October 2014 to receive the poliovirus therapy after undergoing unsuccessful treatment elsewhere for glioblastoma.
Sacrifice, commitment and, most of all, hope inspired Nancy and her husband, Greg, through the months that followed the treatment. After initially responding well and getting great reports during her clinical visits with Dr. Desjardins, who led her care, Nancy took a turn for the worse. She passed away on April 6, 2016 – almost 18 months after receiving the poliovirus therapy at Duke.
The program noted that the months that Nancy survived beyond the typical lifespan for people with glioblastoma were not without challenge, but also full of discovery and joy and gratitude.
For the team at the brain tumor center, Nancy’s death was devastating. But there have been many causes for hope. The first poliovirus patient, Stephanie Lipscomb, received the treatment in 2012 and has now graduated from college and is working as an oncology nurse. Another patient and young father, Brendan Steele, was featured in the program as a three-year survivor after receiving the treatment in 2013.
All of the patients' experiences have offered tremendous insights into the poliovirus therapy and its potential.
As CBS reported, the Duke team, led Bigner, was awarded “breakthrough therapy designation” by the U.S. Food and Drug Administration just last week, which will expedite the development and review of the poliovirus approach. To receive a designation of breakthrough therapy, preliminary evidence must indicate that the treatment shows substantial improvement over available therapy.
“Breakthrough status means that we can work with the highest levels in the FDA to develop the most efficient clinical trial and pathway to fully evaluate the safety and efficacy of the genetically modified poliovirus for treating recurrent glioblastoma,” Bigner said. “Ultimately, we hope the therapy will one day obtain FDA approval.”
Additionally, the 60 Minutes segment reported that the Duke team is moving to open a clinical trial for children with brain tumors, which is planned to begin before the end of the year. It has also received grants to expand the research to explore the therapy’s effect on solid tumors. Laboratory studies are already underway in breast cancer models in work led by Duke's Smita Nair.
Microorganisms often assemble natural products similar to industrial assembly lines. Certain enzymes, non-ribosomal peptide synthetases (NRPS) play a key role in this process. Biotechnologists have now discovered how these enzymes interact with each other, bringing them one step closer to their goal of engineering peptide natural products.READ MORE
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE